Endothel in antagonists and heart failure

Current Hypertension Reports

Volumn 4, Issue 1, 2002, Pages 85-92

  Hürlimann, David ^a   Enseleit, Frank ^a   Noll, Georg ^a   Lüsdher, Thomas F ^a   Ruschitzka, Frank ^a  

^a University Hospital of Psychiatry   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; BOSENTAN; ENDOTHELIN; ENDOTHELIN RECEPTOR; PYRROLIDINE DERIVATIVE; SULFONAMIDE;

CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; DRUG EFFECT; HEMODYNAMICS; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ENDOTHELINS; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; PYRROLIDINES; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 0036480108     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-002-0058-6     Document Type: Article

References (84)

1. Gillum RF: Epidem iology of heart failure in the United States. Am Heart J 1993, 126:1042-1047.
2. Ho KK, Anderson KM, Kannel W B, et al.: Survival after the onset of congestive heart failure in Fram ingham H eart Study subjects. Circulation 1993, 88:107-15.
3. Pitt B, Zannad F, Remme W J, et al.: The effect of spironolactone on m orbidity and m ortality in patients with severe heart failure. Random ized Aldactone Evaluation Study Investigators. N Engl J M 1999, 341:709-717.
4. Yanagisawa M, Kurihara H, Kimura S., et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:41-415.
5. Douglas SA, Ohlstein EH: H um an urotensin-II, the m ost potent m am m alian vasoconstrictor identified to date, as a therapeutic target for the m anagement of cardiovascular disease. Trends Cardiovasc M 2000, 10:229-237.
6. Luscher TF, Boulanger CM, Dohi Y, Yang ZH: Endothelium - derived contracting factors. Hypertension 1992, 19:117-130.
7. Inoue A, Yanagisawa M, Takuwa Y., et al.: The hum an preproendothelin-1 gene. Com plete nucleotide sequence and regulation of expression. J Biol Chem 1989, 264:14954-1499.
8. Emoto N, Yanagisawa M: Endothelin-converting enzym e-2 is a m em brane-bound, phosphoram idon-sensitive m etalloprotease with acidic pH optim. J Biol Chem 1995, 270:15262-15268.
9. Xu D, Emoto N, Giaid A., et al.: ECE-1: a m em brane-bound m etalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994, 78:473-485.
10. de Nucci G., Thomas R, D'Orleans-Juste P, et al.: Pressor effects of circulating endothelin are lim ited by its rem oval in the pulm onary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 1988, 85:9797-9800.
11. Boulanger C, Luscher TF: Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990, 85:587-590.
12. Hu RM, Levin ER, Pedram A, Frank HJ: Atrial natriuretic peptide inhibits the production and secretion of endothelin from cultured endothelial cells. Mediation through the C receptor. J Biol Chem 1992, 267:17384-17389.
13. Sakurai T, Yanagisawa M, Takuwa Y., et al.: Cloning of a cD N A encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990, 348:732-735.
14. Arai H, Hori S, Aramori I., et al.: Cloning and expression of a cD N A encoding an endothelin receptor. Nature 1990, 348:730-732.
15. Levin ER: Endothelins. N Engl J M ed 1995, 333:356-363.
16. Resink TJ, Scott-Burden T, Buhler FR: Endothelin stim ulates phospholipase C in cultured vascular sm ooth m uscle cells. Biochem Biophys Res Commun 1988, 157:1360-1368.
17. Kiowski W, Luscher TF, Linder L, Buhler FR: Endothelin-1-induced vasoconstriction in hum ans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 1991, 83:469-475.
18. Wright CE, Fozard JR: Regional vasodilation is a prom inent feature of the haem odynam ic response to endothelin in anaesthetized, spontaneously hypertensive rats. Eur J Pharm acol 1988, 155(1-2):201-203.
19. Davenport AP, Kuc RE, Maguire J.J., Harland SP: ETA receptors predom inate in the hum an vasculature and m ediate constriction. J Cardiovasc Pharm acol 1995, 26(SUPPL. 3):S265-S267.
20. Verhaar M.C., Strachan FE, Newby D.E., et al.: Endothelin-A receptor antagonist-m ediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998, 97:752-756.
21. Clavell AL, Stingo AJ, Margulies K.B., et al.: Role of endothelin receptor subtypes in the in vivo regulation of renal function. Am J Physiol 1995, 268(3 Pt 2):F455-F460.
22. Kaasjager KA, Shaw S, Koomans H.A., Rabelink TJ: Role of endothelin receptor subtypes in the system ic and renal responses to endothelin-1 in hum ans. J Am Soc Nephrol 1997, 8:32-39.
23. Kannel WB, Castelli WP, McNamara P.M., et al.: Role of blood pressure in the developm ent of congestive heart failure. The Fram ingham study. N Engl J M ed 1972, 287:781-787.
24. Levy D, Larson MG, Vasan R.S., et al.: The progression from hypertension to congestive heart failure. JAMA 1996, 275:1557-1562.
25. Park JB, Schiffrin EL: ET(A) receptor antagonist prevents blood pressure elevation and vascular rem odeling in aldosterone-infused rats. Hypertension 2001, 37:14-1449.
26. Ruschitzka F, Quaschning T, Noll G., et al.: Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide. Circulation 2001, 103:3129-3135.
27. Ehmke H, Faulhaber J, Munter K., et al.: Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension 1999, 33:954-960.
28. Moreau P, d'Uscio LV, Shaw S, et al: Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 1997, 96:1593-1597.
29. d'Uscio L.V., Moreau P, Shaw S., et al.: Effects of chronic ETAreceptor blockade in angiotensin II-induced hypertension. Hypertension 1997, 29(1 Pt 2):435-441.
30. Barton M, Shaw S, d'Uscio LV, et al: Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzym e activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 1997, 238:861-865.
31. Barton M, d'Uscio LV, Shaw S, et al: ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998, 31(1 Pt 2):49-504.
32. Moreau P, d'Uscio LV, Shaw S, et al: Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 1997, 96:1593-1597.
33. Taddei S, Virdis A, Ghiadoni L., et al.: Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 1999, 100:1680-1683.
34. Saito Y, Nakao K, Mukoyama M., Imura H: Increased plasm a endothelin level in patients with essential hypertension. N Engl J M ed 1990, 322:205.
35. Miyauchi T, Yanagisawa M, Iida K., et al.: Age-and sex-related variation of plasm a endothelin-1 concentration in norm al and hypertensive subjects. Am Heart J 1992, 123(4 Pt 1):1092-1093.
36. Krum H, Viskoper RJ, Lacourciere Y, et al: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J M ed 1998, 338:784-790.
37. Nakov RPE, Eberle S: LU-135252: an endothelin a receptor antagonist for treatm ent of hypertension, dose response, efficacy and safety. The H EAT study: Hypertension, Endothelin Antagonsit Treatm ent. Eur Heart J 2001, 2:611.
38. Cody RJ, Haas GJ, Binkley P.F., et al.: Plasm a endothelin correlates with the extent of pulm onary hypertension in patients with chronic congestive heart failure. Circulation 1992, 85:504-509.
39. Stewart DJ, Cernacek P, Costello K.B., Rouleau JL: Elevated endothelin-1 in heart failure and loss of norm al response to postural change. Circulation 1992, 85:510-517.
40. Wei CM, Lerman A, Rodeheffer R.J., et al.: Endothelin in hum an congestive heart failure. Circulation 1994, 89:1580-1586.
41. Pacher R, Stanek B, Hulsmann M., et al.: Prognostic im pact of big endothelin-1 plasm a concentrations com pared with invasive hem odynam ic evaluation in severe heart failure. J Am Coll Cardiol 1996, 27:63-641.
42. Teerlink JR, Loffler BM, Hess P, et al: Role of endothelin in the m aintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation 1994, 90:2510-2518.
43. Ono K, Tsujimoto G, Sakamoto A., et al.: Endothelin-A receptor m ediates cardiac inhibition by regulating calcium and potassium currents. Nature 1994, 370:301-304.
44. Kelly RA, Eid H, Kramer B.K., et al.: Endothelin enhances the contractile responsiveness of adult rat ventricular m yocytes to calcium by a pertussis toxin-sensitive pathway. J Clin Invest 1990, 86:1164-171.
45. James AF, Xie LH, Fujitani Y, et al: Inhibition of the cardiac protein kinase A-dependent chloride conductance by endothelin-1. Nature 1994, 370:297-300.
46. Ito H, Hirata Y, Hiroe M., et al.: Endothelin-1 induces hypertrophy with enhanced expression of m uscle-specific genes in cultured neonatal rat cardiom yocytes. Circ Res 1991, 69:209-215.
47. McClellan G, Weisberg A, Winegrad S: Effect of endothelin-1 on actom yosin ATPase activity. Im plications for the efficiency of contraction. Circ Res 1996, 78:104-1050.
48. Sakai S, Miyauchi T, Sakurai T., et al.: Pulm onary hypertension caused by congestive heart failure is am eliorated by longterm application of an endothelin receptor antagonist. Increased expression of endothelin-1 m essenger ribonucleic acid and endothelin-1-like im m unoreactivity in the lung in congestive heart failure in rats. J Am Coll Cardiol 1996, 28:1580-1588.
49. Fukuchi M, Giaid A: Expression of endothelin-1 and endothelinconverting enzym e-1 m RNAs and proteins in failing hum an hearts. J Cardiovasc Pharmacol 1998, 31(SUPPL. 1):S421-S423.
50. Zolk O, Quattek J, Sitzler G., et al.: Expression of endothelin-1, endothelin-converting enzym e, and endothelin receptors in chronic heart failure. Circulation 1999, 99:2118-2123.
51. Pacher R, Bergler-Klein J, Globits S., et al.: Plasm a big endothelin-1 concentrations in congestive heart failure patients with or without system ic hypertension. Am J Cardiol 1993, 71:1293-1299.
52. Pousset F, Isnard R, Lechat P., et al.: Prognostic value of plasm a endothelin-1 in patients with chronic heart failure. Eur Heart J 1997, 18:254-258.
53. Hulsmann M, Stanek B, Frey B., et al.: Value of cardiopulm onary exercise testing and big endothelin plasm a levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998, 32:1695-1700.
54. Ponicke K, Vogelsang M, Heinroth M., et al.: Endothelin receptors in the failing and nonfailing hum an heart. Circulation 1998, 97:74-751.
55. Thomas PB, Liu EC, Webb M L, et al.: Exogenous effects and endogenous production of endothelin in cardiac m yocytes: potential significance in heart failure. Am J Physiol 1996, 271:H2629-H2637.
56. MacCarthy PA, Grocott-Mason R, Prendergast B.D., Shah AM: Contrasting inotropic effects of endogenous endothelin in the norm al and failing hum an heart: studies with an intracoronary ET(A) receptor antagonist. Circulation 2000, 101:142-147.
57. Torre-Amione G., Young JB, Durand J, et al: H em odynam ic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 2001, 103:973-980.
58. Torre-Amione G., Durand JB, Nagueh S, et al: A pilot safety trial of prolonged (48 h) infusion of the dual endothelinreceptor antagonist tezosentan in patients with advanced heart failure. Chest 2001, 120:460-466.
59. Wenzel RR, Fleisch M, Shaw S., et al.: Hem odynam ic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 1998, 98:2235-240.
60. Kiowski W, Sutsch G, Hunziker P., et al.: Evidence for endothelin-1-m ediated vasoconstriction in severe chronic heart failure. Lancet 1995, 346:732-736.
61. Sutsch G, Kiowski W, Yan X.W., et al.: Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with sym ptom atic severe chronic heart failure. Circulation 1998, 98:2262-268.
62. Packer M, Charlon V, Caspi A., et al.: Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure-results from the REACH-1 trial. Circulation 1998, 98(Suppl S):12.
63. Hirata Y, Takagi Y, Fukuda Y., Marumo F: Endothelin is a potent m itogen for rat vascular sm ooth m uscle cells. Atherosclerosis 1989, 78:225-28.
64. Sumner M.J., Cannon TR, Mundin J.W., et al.: Endothelin ETA and ETB receptors m ediate vascular sm ooth m uscle contraction. Br J Pharm acol 1992, 107:858-860.
65. Seo B, Oemar BS, Siebenmann R, et al: Both ETA and ETB receptors m ediate contraction to endothelin-1 in hum an blood vessels. Circulation 1994, 89:1203-1208.
66. Lin HY, Kaji EH, Winkel G.K., et al.: Cloning and functional expression of a vascular sm ooth m uscle endothelin 1 receptor. Proc Natl Acad Sci U S A 1991, 88:3185-3189.
67. Dupuis J, Goresky CA, Fournier A: Pulm onary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 1996, 81:1510-1515.
68. Dupuis J, Stewart DJ, Cernacek P, Gosselin G: Hum an pulm onary circulation is an im portant site for both clearance and production of endothelin-1. Circulation 1996, 94:1578-1584.
69. Ozaki S, Ohwaki K, Ihara M., et al.: ETB-m ediated regulation of extracellular levels of endothelin-1 in cultured hum an endothelial cells. Biochem Biophys Res Commun 1995, 209:483-489.
70. Fukuroda T, Fujikawa T, Ozaki S., et al.: Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994, 199:1461-1465.
71. Strachan FE, Spratt JC, Wilkinson I.B., et al.: System ic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 1999, 33:581-585.
72. Wada A, Tsutamoto T, Fukai D., et al.: Com parison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. J Am Coll Cardiol 1997, 30:1385-1392.
73. Dupuis J, Rouleau JL, Cernacek P: Reduced pulm onary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to m yocardial infarction. Circulation 1998, 98:1684-1687.
74. Cowburn PJ, Cleland JG, McArthur J.D., et al.: Endothelin B receptors are functionally im portant in m ediating vasoconstriction in the system ic circulation in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 1999, 33:932-938.
75. Spieker LE, Mitrovic V, Noll G., et al.: Acute hem odynam ic and neurohum oral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators. J Am Coll Cardiol 2000, 35:1745-1752.
76. Ruschitzka F, Enseleit F, Mitrovic V., et al.: Chronic selective ETA receptor in congestive heart failure. The HEAT Trial. Circulation 2000, 102(Suppl):2876.
77. Smith W IB, LeJemtel T., Iteld B, et al.: Im proved hem odynam ics with ET(A) selective receptor antagonist BM S-193884 in patients with heart failure (abstr). J Am Coll Cardiol 2000, 34:241A.
78. Qiu C, Ding SS, Hess P, et al: Endothelin m ediates the altered renal hem odynam ics associated with experim ental congestive heart failure. J Cardiovasc Pharm acol 2001, 38:317-324.
79. Cowburn PJ, Cleland JG, McArthur J.D., et al.: Short-term haem odynam ic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure. Lancet 1998, 352:201-202.
80. Cowburn PJ, McDonagh TA, Cleland JGF, et al.: Adverse hem odynam ic effects of a selective endothelin ETB receptor antagonist in patients with chronic heart failure: reversal with a selective endothelin ETA receptor antagonist. Circulation 1998, 98(Suppl):I-718.
81. Chen HH, McKinley LJ, Salz L, et al: Safety and efficacy of an orally active selective entothelin ETA receptor antagonist in m oderate-severe hum an chronic heart failure. Eur J Heart Failure 1999, 1(Suppl):76.
82. Krum HCV, Widmann T, Packer M: Long-term, open-label experience with an endothelin receptor antagonist, bosentan, in patients with severe chronic heart failure. Circulation 1999, 100(Suppl):I-646-I-647.
83. Torre-Amione GDJ, Bozkurt B., Durand J, et al.: Results of a randomized, placebo-controlled, hem odynam ic trial with an intravenous endothelin-1 receptor antagonist in patients with congestive heart failure. Circulation 1999, 100(Suppl):76.
84. Givertz MM, Colucci WS, LeJemtel T.H., et al.: Acute endothelin A receptor blockade causes selective pulm onary vasodilation in patients with chronic heart failure. Circulation 2000, 101:292-2927.